Ovarian Cancer Clinical Trials & Research

Doctors at Memorial Sloan Kettering are constantly working to improve treatment for ovarian cancer through clinical trials. Participating in a clinical trial may give you access to treatments that are not widely available elsewhere, and may offer additional options if your cancer has returned after standard treatment.

Our doctors lead clinical trials that test new drugs and drug combinations, surgical approaches, and strategies for preserving quality of life during and after treatment. We can help determine which clinical trials are right for you.

The following clinical trials for ovarian cancer are currently enrolling new patients. To learn more about a particular study, choose from the list below.

and/or
27 Clinical Trials found
A Phase 1B/2 Study of ACR-368 Alone and with Gemcitabine in People with Ovarian, Endometrial, or Urothelial Cancer
Researchers in this study are assessing the drug ACR-368 alone and in combination with increasing doses of low-dose gemcitabine in people with ovarian, endometrial, or urothelial (bladder) cancer that has come back despite prior treatment. ACR-368 works by stopping cancer cells from repairing damage to themselves and their DNA (genes). Gemcitabine damages the DNA inside cancer cells and prevents the cells from multiplying.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
Researchers want to see how well a new combination of drugs works to treat low-grade serous ovarian cancer. The drugs are avutometinib, defactinib, and letrozole. The people in this study have ovarian cancer that cannot be completely removed with surgery.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Datopotamab Deruxtecan Alone or With Other Anti-Cancer Drugs in People Endometrial, Ovarian, and Urothelial Cancers
Researchers want to see how well datopotamab deruxtecan (Dato-DXd) works alone and with other drugs against cancer. The people in this study have endometrial, ovarian, or urothelial cancer that has metastasized (spread).
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of IMNN-001 on Second-Look Surgery in Combination With Bevacizumab and Chemotherapy in People Newly Diagnosed With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Researchers want to see if adding IMNN-001 to standard treatment works well against advanced gynecologic cancers. The people in this study have newly diagnosed ovarian, fallopian tube, or primary peritoneal cancers.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Pembrolizumab Immunotherapy Plus Standard Treatment in People With Ovarian Cancer
Researchers want to see if combining pembrolizumab immunotherapy with standard treatment works well for people with ovarian cancer. The people in this study have ovarian cancer with minimal residual disease (MRD). MRD is a small amount of cancer cells remaining in the body after treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Raludotatug Deruxtecan in People With Advanced Solid Tumors
Researchers want to see how well raludotatug deruxtecan (R-DXd) works against advanced solid tumors. The people in this study have the following cancers, which have spread despite treatment:
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Selumetinib and Olaparib or Selumetinib Alone for Ovarian and Endometrial Cancers with Certain Genetic Changes
In this study, researchers are comparing selumetinib plus olaparib to selumetinib alone to treat endometrial or ovarian cancer. People in this study have cancer that came back or keeps growing after treatment. In addition, their cancers have a change (mutation or variant) in a RAS gene.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of VS-6766 and Defactinib in People with Advanced Mesonephric Gynecologic Cancer
Mesonephric cancer is a rare gynecologic cancer. The purpose of this study is to assess the safety and effectiveness of giving VS-6766 and defactinib together in people with advanced or recurrent mesonephric gynecologic cancers.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 3 Study of Avutometinib Plus Defactinib Versus Standard Treatment for People With Low-Grade Serous Ovarian Cancer
In this study, researchers are comparing a combination of two new drugs with standard treatment for ovarian cancer. The two drugs are avutometinib and defactinib. The people in this study have low-grade serous ovarian cancer that came back after treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 3 Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus No HIPEC followed by Niraparib in People Newly Diagnosed With Advanced Ovarian Cancer
Hyperthermic intraperitoneal chemotherapy (HIPEC) involves giving heated chemotherapy directly into the belly immediately after surgery to remove an abdominal cancer. Researchers are doing this study to see if HIPEC improves outcomes in people with ovarian cancer. The people in this study have newly diagnosed stage 3 or 4 ovarian cancer.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau